Cite
HARVARD Citation
De Jaeghere, E. et al. (n.d.). 2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial. International journal of gynecological cancer. pp. A187-A188. [Online].